

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07K 5/06, C07D 487/04, 471/04, A61K 31/395 // (C07D 487/04, 209:00, 209:00) (C07D 471/04, 221:00, 209:00) (C07D 487/04, 223:00, 209:00) (C07D 487/04, 225:00, 209:00)</b>	<b>A1</b>	<b>(11) International Publication Number: WO 97/05160</b> <b>(43) International Publication Date: 13 February 1997 (13.02.97)</b>
<b>(21) International Application Number: PCT/EP96/03167</b> <b>(22) International Filing Date: 18 July 1996 (18.07.96)</b> <b>(30) Priority Data:</b> MI95A001688      1 August 1995 (01.08.95)      IT <b>(71) Applicant (for all designated States except US): A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. [IT/IT]; Via Sette Santi, 3, I-50131 Firenze (IT).</b> <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only): SALIMBENI, Aldo [IT/IT]; Via Giotto, 1, I-22050 Lomagna (IT). PALEARI, Fabio [IT/IT]; Via Giotto, 1, I-22050 Lomagna (IT). SCOLASTICO, Carlo [IT/IT]; Via Giotto, 1, I-22050 Lomagna (IT). CRISCUOLI, Marco [IT/IT]; Via Giotto, 1, I-22050 Lomagna (IT).</b> <b>(74) Agent: MINOJA, Fabrizio; Studio Consulenza Brevettuale, Via Rossini, 8, I-20122 Milano (IT).</b>		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title: BICYCLIC LACTAM DERIVATIVES AS THROMBIN INHIBITORS</b> <b>(57) Abstract</b>  Bicyclic lactams containing an arginine residue, which can be of use in therapy as thrombin inhibitors, are disclosed.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LT	Lithuania	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

BICYCLIC LACTAM DERIVATIVES AS THROMBIN INHIBITORS

The present invention relates to bicyclic lactam derivatives with antithrombotic activity, the processes for the preparation thereof, pharmaceutical compositions containing them and the use thereof as therapeutical agents.

The object of the invention are novel bicyclic lactam derivatives having an arginine residue, the salts and hydrates thereof, in diastereomerically pure forms or as stereoisomeric mixtures, having inhibitory activity on some serine-proteases. More particularly, the compounds turned out to be active in inhibiting the action of the enzyme thrombin and therefore can be used as antithrombotic, antiaggregating or anticoagulant agents. The novel derivatives are characterized by having a bicyclic lactam residue which is capable of acting as a conformationally constricted analogue of a peptidic sequence, such as the one consisting of Phe-Pro-Arg, which is present in fibrinogen structure and is considered important for recognizing the thrombin active site. A number of examples of thrombin inhibitors are known, which are based on structural changes of the sequence Phe-Pro-Arg, see for example Patents US n° 4,478,745, US n° 4,399,065, EP 526,877, US n° 697,987 and papers by Bajusz et al., J. Med. Chem., 1990, 33, 1729-1735 and Kettner et al., Thromb. Res., 1979, 14, 969-973.

The compounds of the invention have general formula I:



wherein:

- 10
- m is 0, 1, 2 or 3;
  - $R_1$  is a group of formula  $-CHO$ ,  $-CH_2OH$ ,  $COOH$ ,  $-B(OH)_2$ ;
  - $R_2$ ,  $R_3$  are independently hydrogen,  $COOR_7$ ,  $C_1-C_4$  alkyl, benzyl,  $-NO_2$ ;

15

  - $R_4$ ,  $R_5$  are independently hydrogen,  $NR_8R_9$ , straight or branched  $C_1-C_7$  alkyl,  $C_3-C_7$  cycloalkyl or an arylalkyl or heteroarylalkyl group, optionally substituted at the ring with one or more substituents such as halogen (Cl, Br, I), methoxyl, trifluoromethyl, straight or branched  $C_1-C_7$  alkyl;

20

  - $R_6$  is hydrogen, straight or branched  $C_1-C_7$  alkyl,  $C_3-C_7$  cycloalkyl or an aryl, heteroaryl, arylalkyl or heteroarylalkyl group, optionally substituted at the ring with one or more substituents such as


25

  - halogen (Cl, Br, I), methoxy, trifluoromethyl, straight or branched  $C_1-C_7$  alkyl;
  - $R_7$  is  $C_1-C_4$  alkyl, benzyl;
  - $R_8$ ,  $R_9$  are independently hydrogen, straight or branched  $C_1-C_7$  alkyl or a group of general formula

30

  - $-W-Q$  wherein:

3



- Q can be a phenyl, benzyl, naphthyl, quinolyl, naphthylmethyl, tetrahydroquinolyl, tetrahydro-isoquinolyl group, optionally substituted with one or more groups such as halogen (Cl, Br, I), straight or branched C<sub>1</sub>-C<sub>7</sub> alkyl, methoxy, trifluoromethyl.

The compounds of the invention form, with various both inorganic and organic acids, salts which also are an object of this invention. Said salts include for example hydrochlorides, hydrobromides, sulfates, phosphates, maleates, fumarates.

Examples of C<sub>1</sub>-C<sub>7</sub> alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl.

Examples of C<sub>3</sub>-C<sub>7</sub> cycloalkyl groups are cyclopropyl, cyclopentyl, cyclohexyl.

Aryl groups are preferably phenyl and naphthyl. Heteroaryl groups are preferably thienyl, quinolyl or tetrahydroquinolyl. Examples of arylalkyl groups include benzyl and phenethyl, preferably benzyl. Examples of heteroarylalkyl groups comprise furylmethyl and thienylmethyl.

Examples of R<sub>4</sub> and/or R<sub>5</sub> groups are benzyl, thienylmethyl, amino, acetylamino, methylamino, dimethylamino, t-butoxycarbonylamino, benzyloxycarbonylamino, naphthylsulfonylamino, quinolylsulfonylamino, benzylsulfonylamino, naphthylmethylsulfonylamino, ethylamino, tetrahydroquinolylsulfonylamino.

Examples of R<sub>6</sub> groups are phenyl, thienyl, methyl,

ethyl.

Preferred compounds of formula I are those wherein m is 2, R<sub>1</sub> is -CHO and R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> have the meanings reported above.

5 Other preferred compounds of formula I are those wherein m is 1, R<sub>1</sub> is -CHO and R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> have the meanings reported above.

Particularly preferred compounds are those wherein R<sub>4</sub> and/or R<sub>5</sub> are an arylalkyl, heteroarylalkyl group optionally substituted as indicated above, or a NR<sub>8</sub>R<sub>9</sub> group other particularly preferred compounds are those wherein R<sub>6</sub> is an aryl, heteroaryl, arylalkyl or heteroarylalkyl group, optionally substituted as indicated above, and R<sub>4</sub> and/or R<sub>5</sub> are a protected amino group. Most preferred compounds are the following:

- N<sup>d</sup>-[[6-acetylamino-octahydropyrrolo[1,2-a]azepin-5-one-3-yl]carbonyl]-L-arginine aldehyde,
- N<sup>d</sup>-[[6-methylamino-octahydropyrrolo[1,2-a]azepin-5-one-3-yl]carbonyl]-L-arginine aldehyde,
- 20 - N<sup>d</sup>-[[6-[(benzylsulfonyl)amino]-octahydropyrrolo-[1,2-a]azepin-5-one-3-yl]carbonyl]-L-arginine aldehyde,
- N<sup>d</sup>-[[6-[[[(naphthalen-1-yl)methyl]sulfonyl]amino]-octahydropyrrolo[1,2-a]azepin-5-one-3-yl]carbonyl]-L-arginine aldehyde,
- 25 - N<sup>d</sup>-[[6-[[[(naphthalen-2-yl)methyl]sulfonyl]amino]-octahydropyrrolo[1,2-a]azepin-5-one-3-yl]carbonyl]-L-arginine aldehyde,
- N<sup>d</sup>-[[6-[[[(3-methylquinolin-8-yl)sulfonyl]amino]-octahydropyrrolo[1,2-a]azepin-5-one-3-yl]carbonyl]-L-arginine aldehyde,
- 30 - N<sup>d</sup>-[[6-benzyl-octahydroindolizin-5-one-3-yl]carbonyl]-

L-arginine aldehyde,

- N<sup>α</sup>-[[6-[(thiophen-2-yl)methyl]-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

- N<sup>α</sup>-[[6-[(naphthalen-2-yl)methyl]octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

- N<sup>α</sup>-[[6-[(naphthalen-1-yl)methyl]-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

- N<sup>α</sup>-[[6-acetylamino-6-benzyl-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

-N<sup>α</sup>-[[6-benzyl-6-methylamino-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,


-N<sup>α</sup>-[[6-benzyl-6-[(t-butoxycarbonyl)amino]-octahydroindolizin-5-one-3-yl]-L-arginine aldehyde,

-N<sup>α</sup>-[[6-amino-7-phenyl-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

-N<sup>α</sup>-[[6-(methylamino)-7-phenyl-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

-N<sup>α</sup>-[[6-(acetylamino)-7-phenyl-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde.

According to the invention, compounds of general formula I can be obtained starting from intermediates of general formula VIII




wherein R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and m have the meanings reported above, removing the protective group(s) on the guanidine residue. The deprotection reaction, where R<sub>2</sub>

6

(R<sub>3</sub>) represents a benzyl, nitro or benzyloxycarbonyl group, can be carried out in solvents such as C<sub>1</sub>-C<sub>4</sub> alcohols, ethyl acetate, tetrahydrofuran, in the presence of a Pd or Pt catalyst on charcoal under hydrogen atmosphere, or, where R<sub>2</sub> (R<sub>3</sub>) is a t-butoxycarbonyl group, by treatment with strong organic or inorganic acids in apolar solvents such as dioxane or tetrahydrofuran.


The intermediates of general formula VIII can be obtained from compounds of general formula VII



wherein R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and m have the meanings reported above, by reduction with, for example, metal hydrides, such as LiAlH<sub>4</sub>, NaBH<sub>4</sub>, NaCNBH<sub>4</sub>, LiBH<sub>4</sub>, LiBEt<sub>3</sub>H, in both apolar and polar solvents, such as ethyl ether, tetrahydrofuran or C<sub>1</sub>-C<sub>4</sub> alcohols, at temperatures from -20°C to room temperature. Intermediates of general formula VII can be obtained by condensation of compounds of general formula VI, the preparation of which is described in literature (see for example Balasubramanian N. et. al, J. Med. Chem., 1993, 36, 300-303) and wherein R<sub>2</sub> and R<sub>3</sub> have the meanings reported above,




5



10

with compounds of general formula V, wherein R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, and m have the meanings reported above and R<sub>10</sub> is hydrogen.

15



20

The condensation reaction can be carried out according to one of the procedures known in literature, used to form peptide or amido bonds (see for example Bodanszky M., Peptide Chemistry, chapter V, pag. 55-72, Springer-Verlag Editor).


25

30

By way of example, dicyclohexylcarbodiimide, diphenyl phosphoryl azide can be used as carboxy-activating agents, or mixed anhydrides can be prepared by reaction with alkyl chloroformates; subsequently the intermediates can be reacted with the amino derivative of general formula VI, in solvents such as dichloromethane, chloroform, tetrahydrofuran, dimethylformamide, at temperatures generally ranging from 0°C to room temperature.

8

Compounds of general formula V can be obtained by cyclization starting from intermediates of general formula IV, wherein  $R_4$  ( $R_5$ ),  $R_6$  and  $m$  have the meanings reported above,  $R_{10}$  can be alkyl  $C_1-C_4$ ,  $X$  can be Br, I or phenylselenenyl.



The cyclization reaction can be carried out in the presence of radicalic initiators, such as  $\alpha, \alpha'$ -azabisisobutyronitrile or dibenzoyl peroxide, by addition of trialkyl- or triphenyl- tin hydrides, in aprotic apolar solvents such as ethyl ether, tetrahydrofuran, benzene, toluene, carbon tetrachloride, at temperatures generally ranging from room temperature to the solvent boiling temperature. Generally the cyclization reaction is stereoselective and among the various possible stereoisomers, a diastereoisomer mainly forms. When a mixture of stereoisomers is obtained, the single diastereoisomers can be separated and purified by means of crystallization and/or chromatographic techniques.

The compounds of general formula IV can easily be obtained starting from compounds of formula IV', wherein  $R_4$  ( $R_5$ ),  $R_6$ ,  $R_{10}$  and  $m$  have the meanings reported above and  $X$  is hydroxyl, by transformation of the alcohol into the corresponding mesylate, trifluoromethanesulfonate or


tosylate and subsequent reaction with sodium or potassium bromides or iodides, in dipolar aprotic solvents such as acetone, dimethylformamide, dimethylsulfoxide at the solvent boiling temperature.

5 When X represents a phenylselenenyl group, the transformation can be carried out starting from the corresponding alcohol, by treatment with phenylselenophthalimide, in the presence of tributyl phosphine, in solvents such as tetrahydrofuran or


10 dichloromethane at temperatures ranging from 0°C to room temperature.

The intermediates of general formula IV' can be obtained starting from intermediates of general formula III, the preparation of which is described in

15 literature, (see for example, J. Am. Chem. Soc., 1984, 106, 4439-4547), wherein X, R<sub>10</sub> and m have the meanings reported above



by coupling with compounds of general formula II, wherein R<sub>4</sub> (R<sub>5</sub>) and R<sub>6</sub> have the meanings reported above.



30 The condensation reaction can be carried out in the presence of condensing agents, for example

10

dicyclohexylcarbodiimide, in aprotic apolar solvents such as tetrahydrofuran or dichloromethane, at temperatures ranging from 0°C to room temperature.

Intermediates of general formula II, wherein R<sub>6</sub> has  
5 the meanings reported above and R<sub>4</sub> (R<sub>5</sub>) can be an acetylamino, t-butoxycarbonylamino or benzyloxycarbonylamino group, are generally commercially available or easily obtainable starting from the corresponding amino acids, according to what described in literature (see  
10 for example Kolar A. J. et al, Synthesis, 1977, 457-459 and Ranganathan D. et al., J. Chem. Soc. Chem. Commun., 1992, (16), 1145-1147).

The compounds described in the present invention act as thrombin inhibitors. In order to characterize and  
15 evaluate the efficacy thereof, an in vitro test for the inhibition of human thrombin (in the presence of tosylglycyl-prolyl-arginine-4-nitroaniline acetate as substrate) has been selected (Lotttemberg et al., Methods in Enzymology, 1981, (80), 341-361).

20 The compounds of the invention proved to be active in the above test, showing IC<sub>50</sub> values lower than 5 µM. The compounds of the invention can therefore be used as active principles of pharmaceutical compositions with antithrombotic activity. The compositions of the  
25 invention can be prepared according to conventional techniques and excipients, and will contain typically 1 to 1000 mg of compounds I, and will be administered 1 to 4 times a day through the oral, parenteral, transdermal routes or any other convenient administration route.

30 For example, compound (3S,6S,9aS)-N<sup>α</sup>-[[[6-[[[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonyl]amino]-

11

octahydropyrrolo[1,2-a]azepin-5-one-3-yl]carbonyl]-L-  
arginine aldehyde hydrochloride (example 8p) showed to  
have an IC<sub>50</sub> value of 0.018 µM. Another compound,  
(3S,6R\*,8aS)-N<sup>a</sup>-[[6-benzyl-octahydroindolizin-5-one-3-  
5 yl]carbonyl-L-arginine aldehyde hydrochloride (example  
8g) proved to have an IC<sub>50</sub> value of 4.60 µM.

The following examples further illustrate the  
invention, without limiting it.

Melting points are not corrected, the identity of  
10 the compounds and their purity have been determined by  
elementary analysis (C, H, N), NMR, IR and mass  
spectroscopies.

Example 1

(2S,5R)-1-[2-(acetylamino)propenoyl]-2-(t-butoxycarbo-  
15 nyl)-5-(2-hydroxyethyl)pyrrolidine

A solution of (2S,5R)-2-(t-butoxycarbonyl)-5-(2-  
hydroxyethyl)-pyrrolidine (10 g, 46.5 mmol) in 150 ml  
of anhydrous THF is added with DCC (14.4 g, 70 mmol).  
When dissolution has been completed, 2-acetylamino-  
20 acrylic acid is added (6 g, 46.5 mmol) and stirring  
for 18 h at room temperature. The solution is diluted  
with Et<sub>2</sub>O to decrease the solubility of the formed urea,  
then it is filtered and concentrated to dryness. After  
purification by flash chromatography (AcOEt-MeOH 85:15),  
25 12.1 g of the product are obtained, as a yellow spongy  
solid (80% yield).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>)

δ: 1.44 (9H, s), 1.51-2.45 (6H, m), 2.00 (3H, s); 3.65  
(3H, m), 4.45 (1H, m), 4.65 (1H, m), 4.82 (1H, s), 5.32  
30 (1H, s), 8.5 (1H, s)

<sup>13</sup>C-NMR (CDCl<sub>3</sub>)

12

8: 23.78, 28.49, 30.35, 30.70, 38.91, 55.82, 59.97, 64.72, 82.73, 104.75, 169.93.

Analogously are prepared:

- 5 a) (2S,5R)-1-[2-(acetylamino)-3-phenylpropenoyl]-2-(t-butoxycarbonyl)-5-(2-hydroxyethyl)pyrrolidine,  
<sup>1</sup>H-NMR (CDCl<sub>3</sub>)  
8: 1.28 (9H, s), 1.6-2.50 (6H, m), 2.1 (3H, s), 3.55 (2H, m), 3.9 (1H, m), 4.5 (1H, m), 4.9 (1H, dd), 5.9 (1H, s), 7.2-7.6 (5H, m), 8.5 (1H, s)
- 10 <sup>13</sup>C-NMR (CDCl<sub>3</sub>)  
8: 22.36, 27.65, 29.52, 30.31, 38.37, 54.59, 59.15, 64.78, 81.70, 120.44, 128.31, 128.47, 128.80, 129.72, 129.76, 133.25, 170.25, 171.38, 172.01.
- 15 b) (2S,5R)-1-[2-(acetylamino)-2-butenoyl]-2-t-butoxycarbonyl-5-(2-hydroxyethyl)pyrrolidine  
<sup>1</sup>H-NMR (CDCl<sub>3</sub>)  
8: 1.5 (9H, s), 1.65 (3H, d), 1.6-2.4 (6H, m), 3.65 (2H, m), 4.51 (1H, s), 4.85 (1H, dd), 4.52 (1H, q), 8.52 (1H, s)
- 20 <sup>13</sup>C-MNR (CDCl<sub>3</sub>)  
8: 11.76, 21.94, 27.73, 29.49, 30.08, 38.21, 54.49, 59.07, 64.69, 81.60, 118.45, 131.57, 170.11, 171.54, 172.20.
- 25 c) (2S,5R)-1-[2-(acetylamino)-3-phenylpropenoyl]-2-t-butoxycarbonyl-5-(hydroxymethyl)pyrrolidine,  
d) (2S,5R)-1-[2-(acetylamino)-2-butenoyl]-2-t-butoxycarbonyl-5-(hydroxymethyl)pyrrolidine,  
e) (2S,5R)-1-[2-(acetylamino)propenoyl]-2-t-butoxycarbonyl-5-(hydroxymethyl)pyrrolidine,
- 30 f) (2S,5R)-2-[(t-butoxycarbonyl)amino]-5-(2-hydroxyethyl)-1-(3-phenylpropenoyl)pyrrolidine,

13

g) (2S,5R)-1-[2-[(benzyloxycarbonyl)amino]propenoyl]-2-(t-butoxycarbonyl)-5-(2-hydroxyethyl)-pyrrolidine,

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 1.25-2.15 (m, 6H); 1.52 (s, 9H); 3.47 (m, 2H); 4.20 (m, 2H); 5.05 (m, 2H); 5.66 (s, 1H); 7.20-7.40 (m, 6H),

h) (2S,5R)-1-[2-[(benzyloxycarbonyl)amino]-3-phenylpropenoyl]-2-(t-butoxycarbonyl)-5-(2-hydroxyethyl)-pyrrolidine,

i) (2S,5R)-1-[2-[(benzyloxycarbonyl)amino]-3-(thiophen-2-yl)propenoyl]-2-(t-butoxycarbonyl)-5-(2-hydroxyethyl)pyrrolidine,

l) (2S,5R)-1-(3-phenylpropenoyl)-2-(t-butoxycarbonyl)-5-(2-hydroxyethyl)-pyrrolidine,

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 1.47 (s, 9H); 1.55-2.51 (m, 6H); 3.71 (m, 2H); 4.50 (t, 1H); 4.75 (m, 2H); 6.59 (d, 1H); 7.30-7.60 (m, 5H); 7.70 (d, 1H).

m) (2S,5R)-1-[2-[(benzylsulfonyl)amino]propenoyl]-2-(t-butoxycarbonyl)-5-(2-hydroxyethyl)-pyrrolidine,

n) (2S,5R)-2-(t-butoxycarbonyl)-1-[2-[[[(naphthalen-1-yl)methyl]sulfonyl]amino]propenoyl]-5-(2-hydroxyethyl)-pyrrolidine,

o) (2S,5R)-2-(t-butoxycarbonyl)-1-[2-[[[(3-methylquinolin-8-yl)sulfonyl]amino]propenoyl]-5-(2-hydroxyethyl)-pyrrolidine,

p) (2S,5R)-2-(t-butoxycarbonyl)-1-[2-[[[(naphthalen-2-yl)methyl]sulfonyl]amino]propenoyl]-5-(2-hydroxyethyl)-pyrrolidine,

q) (2S,5R)-2-(t-butoxycarbonyl)-1-(3-phenylpropenoyl)-5-(3-hydroxypropyl)-pyrrolidine.

Example 2(2S,5R)-1-[2-(acetylamino)propenoyl]-2-(t-butoxycarbonyl)-5-[2-(phenylselenyl)ethyl]pyrrolidine

A solution of (2S,5R)-1-[2-(acetylamino)propenoyl]-2-(t-butoxycarbonyl)-5-(2-hydroxyethyl)-pyrrolidine (3.5 g, 10.8 mmoles) in 50 ml of anhydrous THF under N<sub>2</sub> atmosphere and at 0°C, is added with tributyl phosphine (4.4 g, 21.6 mmoles) and N-phenylselenophthalimide (6.5 g, 21.6 mmoles). The mixture is stirred for 2h at 0°C, after that solvent is removed under reduced pressure and the residue is purified by flash chromatography (EtOAc-hexane 6:4). 3.2 g of product are obtained, as a slightly yellow solid (54% yield).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>)

δ: 1.46 (9H, s), 2.06 (3H, s), 1.5-2.28 (5H, m), 2.09-2.51 (1H, m), 2.8-3.1 (2H, m), 4.12-4.4 (1H, m), 4.61 (1H, m), 4.83 (1H, s), 5.51 (1H, s), 7.07-7.63 (5H, m), 8.42 (1H, s)

<sup>13</sup>C-NMR (CDCl<sub>3</sub>)

δ: 23.12, 24.13, 27.79, 29.20, 39.76, 58.78, 63.56, 81.65, 103.79, 126.61, 128.90, 132.291, 137.35, 169.34, 171.63.

MS (FAB<sup>+</sup>): m/e 467 (MH<sup>+</sup>)

Analogously are prepared:

a) (2S,5R)-1-[2-(acetylamino)-3-phenylpropenoyl]-2-t-butoxycarbonyl-5-[2-(phenylselenyl)ethyl]pyrrolidine

<sup>1</sup>H-NMR (CDCl<sub>3</sub>)

δ: 1.21 (9H, s), 2.15 (3H, s), 1.1-2.4 (6H, m), 2.89 (2H, m), 4.22 (1H, m), 4.85 (1H, d), 5.61 (1H, s), 7.0-7.6 (10H, m), 10.25 (1H, s)



15

 $^{13}\text{C}$ -NMR ( $\text{CDCl}_3$ )

$\delta$ : 22.27, 24.27, 27.70, 29.45, 29.79, 34.63, 58.24, 64.23, 81.28, 121.08, 126.51, 128.29, 128.41, 128.67, 128.91, 130.31, 132.11, 133.38, 170.25, 170.65, 171.80

- 5 b) (2S,5R)-1-[2-(acetylamino)-2-butenoyl]-2-t-butoxycarbonyl-5-[2-(phenylselenyl)ethyl]pyrrolidine,

 $^1\text{H}$ -NMR ( $\text{CDCl}_3$ )

$\delta$ : 1.52 (9H, s), 2.33 (3H, s), 1.2-2.51 (9H, m), 2.95 (2H, m), 4.33 (1H, m), 4.82 (1H, m), 5.23 (1H, q), 7.1-7.60 (5H, m), 9.65 (1H, s)

 $^{13}\text{C}$ -NMR ( $\text{CDCl}_3$ )

$\delta$ : 11.91, 22.33, 24.33, 27.84, 29.48, 35.99, 58.04, 63.26, 81.31, 118.908, 126.51, 128.85, 132.41

- 15 c) (2S,5R)-1-[2-(acetylamino)-3-phenylpropenoyl]-2-t-butoxycarbonyl-5-[(phenylselenyl)methyl]pyrrolidine,

d) (2S,5R)-1-[2-(acetylamino)2-butenoyl]-2-t-butoxycarbonyl-5-[(phenylselenyl)methyl]pyrrolidine,

- 20 e) (2S,5R)-1-[2-(acetylamino)-propenoyl]-2-t-butoxycarbonyl-5-[(phenylselenyl)methyl]pyrrolidine,

f) (2S,5R)-1-[2-[(benzyloxycarbonyl)amino]propenoyl]-2-(t-butoxycarbonyl)-5-[2-(phenylselenyl)ethyl]pyrrolidine,

- 25 g) (2S,5R)-1-[2-[(benzyloxycarbonyl)amino]-3-(thiophen-2-yl)propenoyl]-2-(t-butoxycarbonyl)-5-[2-(phenylselenyl)ethyl]pyrrolidine,

h) (2S,5R)-2-(t-butoxycarbonyl)-5-[2-(phenylselenyl)ethyl]-1-(3-phenylpropenoyl)-pyrrolidine,

- $^1\text{H}$ -NMR ( $\text{CDCl}_3$ ): 1.47 (s, 9H); 1.70-2.50 (m, 6H); 2.90-3.15 (m, 2H); 4.31-4.52 (m, 2H); 6.85 (d, 1H); 7.10-7.80 (m, 11H)

16

- i) (2S,5R)-2-(t-butoxycarbonyl)-5-[2-(phenylselenyl)-ethyl]-1-[3(thiophen-2-yl)propenoyl]-pyrrolidine,  
1) (2S,5R)-2-(t-butoxycarbonyl)-5-[3-(phenylselenyl)-propyl]-1-(3-phenylpropenoyl)-pyrrolidine.

5 Example 3

(2S,5R)-1-[2-(acetylamino)propenoyl]2-(t-butoxycarbonyl)-5-(2-iodoethyl)-pyrrolidine

A solution of (2S,5R)-1-[2-(acetylamino)propenoyl]-2-(t-butoxycarbonyl)-5-(2-hydroxyethyl)pyrrolidine (10.3  
10 g, 31.5 mmoles) in 200 ml of anhydrous CH<sub>2</sub>Cl<sub>2</sub>, under N<sub>2</sub> atmosphere and cooled at 0°C, is added with the triethylamine (6.1 ml, 44.1 mmoles) and subsequently a solution of methanesulfonyl chloride (3.1 ml, 39.7 mmoles) in 70 ml of CH<sub>2</sub>Cl<sub>2</sub>. The mixture is stirred 0°C  
15 until the starting product disappears, then it is washed repeatedly with water, dried over Na<sub>2</sub>SO<sub>4</sub> and solvent is removed under reduced pressure. The resulting crude mesylate is redissolved in 300 ml of acetone, the solution is added with sodium iodide (22.8 g, 150  
20 mmoles), finally it is refluxed and after 3 h the solvent is removed under reduced pressure. The residue is redissolved in CH<sub>2</sub>Cl<sub>2</sub>, washed with water, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to dryness. After purification by flash chromatography (EtOAc- MeOH 95:5), 11.0 g of a  
25 slightly yellow solid are obtained.

(80% yield)

m.p. 48-50°C (dec)

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 1.45 (s, 9H); 1.52-2.15 (m, 8H); 2.08 (s, 3H); 3.27 (m, 2H); 4.28 (m, 1H) 4.53 (s, 1H); 4.89  
30 (s, 1H); 5.76 (s, 1H); 7.90 (s, 1H)

Analogously are prepared:

17

- a) (2S,5R)-2-(t-butoxycarbonyl)-5-(2-iodoethyl)-1-(3-phenylpropenoyl)-pyrrolidine,
- b) (2S,5R)-2-(t-butoxycarbonyl)-5-(2-iodoethyl)-1-[3-(thiophen-2-yl)propenoyl]-pyrrolidine,
- 5 c) (2S,5R)-2-(t-butoxycarbonyl)-5-(2-bromomethyl)-1-[2-(acetylamino)propenoyl]-pyrrolidine,
- d) (2S,5R)-2-(t-butoxycarbonyl)-1-[2-[(benzyloxycarbonyl)amino]propenoyl]-5-(2-iodoethyl)-pyrrolidine,  
<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 1.33 (s, 9H); 1.30-2.20 (m, 4H); 2.80-  
 10 3.20 (m, 4H); 4.12 (m, 1H); 4.22 (m, 1H); 4.80 (s, 1H);  
 4.86 (s, 2H); 5.72 (s, 1H); 6.90 (s, 1H); 7.35 (m, 5H).
- e) (2S,5R)-2-(t-butoxycarbonyl)-1-(2-butenoyl)-5-(2-iodoethyl)-pyrrolidine,
- f) (2S,5R)-1-[2-[(benzylsulfonyl)amino]propenoyl]-2-  
 15 (t-butoxycarbonyl)-5-(2-iodoethyl)-pyrrolidine,
- g) (2S,5R)-2-(t-butoxycarbonyl)-1-[2-[[[(naphthalen-1-yl)methyl]sulfonyl]amino]propenoyl]-5-(2-iodoethyl)-pyrrolidine,
- h) (2S,5R)-2-(t-butoxycarbonyl)-1-[2-[[[(3-methylquinolin-8-yl)sulfonyl]amino]propenoyl]-5-(2-iodoethyl)-  
 20 pyrrolidine,
- i) (2S,5R)-2-(t-butoxycarbonyl)-1-[2-[[[(naphthalen-2-yl)methyl]sulfonyl]amino]propenoyl]-5-(2-iodoethyl)-pyrrolidine.

25 Example 4

(3S,6S,9aS)-6-acetylamino-3-(t-butoxycarbonyl)-octahydropyrrolo[1,2-a]azepin-5-one

A solution of (2S,5R)-2-(t-butoxycarbonyl)-5-(2-iodoethyl)-1-[2-(acetylamino)propenoyl]-pyrrolidine (8.5  
 30 g, 19.5 mmol) in 1500 ml of anhydrous benzene under reflux and N<sub>2</sub> atmosphere, is added drop by drop during 6

18

h with a solution of  $\text{Bu}_3\text{SnH}$  (6.5 ml, 23.1 mmol) and AIBN (0.65 g, 3.9 mmol) in 350 ml of benzene.

When the reaction is complete, the mixture is cooled at room temperature, the volume is reduced to about 300 ml and KF saturated solution is added. Stirring is continued for 8 h, salts are filtered off through celite, the phases are separated and the organic phase is dried over  $\text{Na}_2\text{SO}_4$ . Upon removal of the solvent under reduced pressure and purification by flash chromatography (EtOAc-MeOH 95:5) 3.7 g of a white foamy solid are obtained (62% yield).

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ )

$\delta$ : 1.46 (9H, s), 1.97 (3H, s), 1.50-2.29 (10H, m), 3.78-3.88 (1H, m), 4.43 (1H, m), 4.50 (1H, dd), 6.94 (1H, d)

$^{13}\text{C-NMR}$  ( $\text{CDCl}_3$ )

$\delta$ : 23.29, 27.95, 27.49, 27.69, 31.14, 32.83, 34.21, 53.24, 59.15, 61.33, 81.48, 169.13, 170.05.

MS (EI): m/e 310

Analogously are prepared:

- a) (3S,6S,7R,9aS)-6-(acetylamino)-3-(t-butoxycarbonyl)-7-methyloctahydropyrrolo[1,2-a]azepin-5-one,

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ )

$\delta$ : 1.50 (9H, s), 1.50-2.52 (7H, m), 3.83 (1H, m), 4.41-4.63 (1H, m), 4.61 (1H, m), 7.12 (1H, db).

- b) (3S,6R,8aR)-6-(acetylamino)-6-(benzyl)-3-(t-butoxycarbonyl)-octahydroindolizin-5-one,

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ ),

$\delta$ : 1.46 (9H, s), 2.0 (3H, s), 1.5-2.1 (6H, m), 2.32 (1H, m), 2.72 (1H, m), 3.1 (1H, m), 3.32 (1H, d), 3.42 (1H, d), 4.25 (1H, m), 6.55 (1H, s), 7.0-7.4 (5H, m)

$^{13}\text{C-NMR}$  ( $\text{CDCl}_3$ )

19

$\delta$ : 24.27, 26.98, 27.75, 27.75, 27.84, 28.16, 30.21, 31.54, 42.18, 58.40, 60.04, 77.43, 126.63, 127.63, 127.28, 127.79, 127.91, 128.22, 130.24.

- c) (3S,6R\*,7aR)-6-acetylamino-6-benzyl-3-(t-butoxycarbonyl)-hexahydropyrrolizin-5-one,
- 5 d) (3S,6R\*,7aR)-6-acetylamino-6-ethyl-3-(t-butoxycarbonyl)-hexahydropyrrolizin-5-one,
- e) (3S,6R\*,7aR)-6-acetylamino-6-methyl-3-(t-butoxycarbonyl)-hexahydropyrrolizin-5-one,
- 10 f) (3S,6R\*,7R\*,8aR)-6-acetylamino-7-phenyl-3-(t-butoxycarbonyl)-octahydroindolizin-5-one,
- g) (3S,6R\*,7R\*,8aR)-6-acetylamino-7-methyl-3-(t-butoxycarbonyl)-octahydroindolizin-5-one,
- h) (3S,6R\*,8aR)-6-acetylamino-3-(t-butoxycarbonyl)-octahydroindolizin-5-one,
- 15 i) (3S,6R\*,8aR)-6-benzyl-3-(t-butoxycarbonyl)octahydroindolizin-5-one,
- l) (3S,6R\*,8aR)-3-(t-butoxycarbonyl)-6-[(thiophen-2-yl)methyl]-octahydroindolizin-5-one,
- 20 m) (3S,6R\*,8aR)-6-[(benzyloxycarbonyl)amino]-3-(t-butoxycarbonyl)-6-[(thiophen-2-yl)methyl]-octahydroindolizin-5-one,
- n) (3S,6S,9aS)-3-(t-butoxycarbonyl)-6-[(benzylsulfonyl)amino]-octahydropyrrolo[1,2-a]azepin-5-one,
- 25 o) (3S,6S,9aS)-3-(t-butoxycarbonyl)-6-[(benzyloxycarbonyl)amino]-octahydropyrrolo[1,2-a]azepin-5-one,
- $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$ : 1.53 (s, 9H); 1.50-2.45 (m, 10H); 3.80 q, 1H); 4.20 (m, 1H); 4.55 (t, 1H); 5.09 (s, 2H); 6.21 (m, 1H); 7.35 (m, 5H).
- 30 p) (3S,6S,9aS)-3-(t-butoxycarbonyl)-6[[[(naphthalen-1-yl)methyl]sulfonyl]amino]-octahydropyrrolo[1,2-

alazepin-5-one,

- q) (3S,6S,9aS)-3-(t-butoxycarbonyl)-6-[[[(3-methylquinolin-8-yl)sulfonyl]amino]-octahydropyrrolo[1,2-alazepin-5-one.

5 Example 5

(3S,6S,9aS)-6-acetylamino-octahydropyrrolo-[1,2-alazepin-5-one-3-carboxylic acid

A solution of (3S,6S,9aS)-3-(t-butoxycarbonyl)-6-acetylamino-octahydropyrrolo[1,2-alazepin-5-one (0.88 g,  
10 2.9 mmols) in 10 ml of anhydrous CH<sub>2</sub>Cl<sub>2</sub> at room temperature, is added with 10 ml of CF<sub>3</sub>COOH. The mixture is stirred until the starting tert-butyl ester disappears and the solvent is removed under reduced pressure. The residue is redissolved in CH<sub>2</sub>Cl<sub>2</sub> and  
15 extracted with 2M Na<sub>2</sub>CO<sub>3</sub>. The alkali aqueous phase is acidified to pH = 2 with 2N HCl and the solvent is evaporated under reduced pressure.

The crude acid is purified by chromatography on a ion exchange resin (DOWEX) eluting with 2N HCl. Upon  
20 removing the solvent under reduced pressure and drying, 0.48 g of a white solid are obtained (67% yield).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 0.95-2.43 (m, 10H); 1.99 (s, 3H); 3.84 (m, 1H); 4.51 (m, 1H); 4.63 (m, 1H); 7.05 (d, 1H).

Analogously are prepared:

- 25 a) (3S,6R,8aR)-6-acetylamino-6-benzyl-octahydroindolizin-5-one-3-carboxylic acid,

m.p. 170-174°C (dec)

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 1.35-2.20 (m, 7H); 2.09 (s, 3H); 2.80 (m, 1H); 3.47 (AB syst., 2H); 4.07 (m, 1H); 4.51 (m,  
30 1H); 7.10-7.25 (m, 5H)

- b) (3S,6R\*,8aS)-6-benzyl-octahydroindolizin-5-one-3-

carboxylic acid,

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$ : 0.95-2.45 (m, 7H); 2.81 (m, 2H); 3.45 (m, 2H); 4.51 (d, 1H); 7.45 (m, 5H),

- 5 c) (3S,6R\*,7R\*,9aS)-6-acetylamino-7-methyl-octahydro-pyrrolo[1,2-a]azepin-5-one-3-carboxylic acid,
- d) (3S,6R\*,8aR)-6-acetylamino-octahydroindolizin-5-one-3-carboxylic acid,
- e) (3S,6S,9aS)-6-[(benzyloxycarbonyl)amino]-octahydro-pyrrolo[1,2-a]azepin-5-one-3-carboxylic acid,
- 10 f) 6-[(thiophen-2-yl)methyl]-octahydroindolizin-5-one-3-carboxylic acid,
- g) (3S,6S,9aS)-6-[[naphthalen-1-yl)sulfonyl]amino]-octahydro-pyrrolo[1,2-a]azepin-5-one-3-carboxylic acid,
- 15 m.p. 192-197°C,
- h) (3S,6S,9aS)-6-[[naphthalen-2-yl)sulfonyl]amino]-octahydro-pyrrolo[1,2-a]azepin-5-one-3-carboxylic acid,
- i) (3S,6R\*,7R\*,8aR)-6-methylamino-7-phenyl-octahydro-indolizin-5-one-3-carboxylic acid,
- 20 l) (3S,6S,9aS)-6-[[benzyl)sulfonyl]amino]-octahydro-pyrrolo[1,2-a]azepin-5-one-3-carboxylic acid,
- $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$ : 1.15-2.37 (m, 10H); 3.17-3.52 (m, 2H); 4.12-4.48 (m, 2H); 4.57 (m, 1H); 5.87 (d, 1H); 7.37 (m,
- 25 5H),
- m) (3S,6S,9aS)-6-[[3-methylquinolin-8-yl)sulfonyl]amino]-octahydro-pyrrolo[1,2-a]azepin-5-one-3-carboxylic acid,
- m.p. 228-232°C,
- 30 n) (3S,6S,9aS)-6-[[[naphthalen-1-yl)methyl]sulfonyl]amino]-octahydro-pyrrolo[1,2-a]azepin-5-one-3-

22

carboxylic acid,

o) (3S,6R\*,9aS)-6-benzyl-octahydropyrrolo-[1,2-a]-  
azepin-5-one-3-carboxylic acid,

m.p. 105-110°C (dec.).

5 Example 6

(3S,6S,9aS)-N<sup>d</sup>-[(6-acetylamino-octahydropyrrolo[1,2-a]-  
azepin-5-one-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-argi-  
nine lactam

A solution of (3S,6S,9aS)-6-(acetylamino)-octa-  
10 hydropyrrolo[1,2-a]azepin-5-one-3-carboxylic acid (0.41  
g, 1.62 mmoles) in 10 ml of anhydrous DMF under N<sub>2</sub>  
atmosphere and cooled at -15°C is added with a syringe  
with, in turn, N-methylmorpholine (0.18 ml, 1.62 mmoles)  
and isobutyl chloroformate (0.23 ml, 1.62 mmoles). The  
15 reaction mixture is stirred for 30 min at -15°C, after  
that a solution of N-methylmorpholine (0.36 ml, 3.24  
mmoles) and N<sup>W</sup>-benzyloxycarbonyl-L-arginine lactam  
hydrochloride (0.6 g, 1.62 mmoles) dissolved in 10 ml of  
DMF is added.

20 The resulting suspension is stirred for 2 h, left  
to warm at room temperature and finally the solvent is  
removed under reduced pressure. The residue is taken up  
with CH<sub>2</sub>Cl<sub>2</sub>, washed with water and with a NaCl saturated  
solution, dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvent is removed  
25 under reduced pressure. After purification by flash  
chromatography (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 95:5) and grinding with  
Et<sub>2</sub>O-hexane, 0.63 g of product are obtained, as a white  
amorphous solid (54% yield).

m.p. 145-150°C (dec); <sup>1</sup>H-NMR (CDCl<sub>3</sub>): 0.95 (d, 1H);  
30 1.20-2.50 (m, 13H); 2.05 (s, 3H); 3.49 (m, 1H); 3.80 (m,  
1H); 4.57 (m, 2H); 4.70 (d, 1H); 4.91 (m, 1H);



23

5.14/5.2H); 6.89 (d, 1H); 7.20-7.50 (m, 10H); 7.63 (d, 1H); 9.50 (m, 2H); MS (FAB<sup>+</sup>): m/z 527.

Analogously are prepared:

- 5 a) (3S,6R,8aR)-N<sup>Q</sup>-[(6-acetylamino-6-benzyl-octahydro-indolizin-5-one-3-yl)carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine lactam,  
m.p. 121-125°C (dec); <sup>1</sup>H-NMR (CDCl<sub>3</sub>): 0.95 (d, 1H); 1.20-2.35 (m, 13H); 2.04 (s, 3H); 3.70 (m, 2H); 4.40-4.73 (m, 3H); 5.12 (s, 2H); 6.25 (d, 1H); 7.05-7.41 (m, 10H); 7.80 (d, 1H); 9.20-9.50 (m, 2H)  
10 MS (FAB<sup>+</sup>): m/z 603
- b) -N<sup>Q</sup>-[[6-acetamido-7-methyloctahydro[1,2-a]azepin-5-one-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine lactam,
- 15 c) -N<sup>Q</sup>-[[6-acetamido-6-benzyl-hexahydropyrrolizin-5-one-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine lactam,
- d) -N<sup>Q</sup>-[[6-acetamido-6-benzyl-hexahydropyrrolizin-5-one-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine lactam,  
20
- e) -N<sup>Q</sup>-[[6-acetamido-6-ethyl-hexahydropyrrolizin-5-one-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine lactam,
- f) -N<sup>Q</sup>-[[6-acetamido-6-methyl-hexahydropyrrolizin-5-one-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine lactam,  
25
- g) (3S,6S,9aS)-N<sup>Q</sup>-[[6-[[[(3-methylquinolin-8-yl)sulfonyl]amino]-octahydropyrrolo[1,2-a]azepin-5-one-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine lactam,  
30
- m.p. 205-210°C (dec.),

24

- h) (3S,6S,9aS)-N<sup>α</sup>-[[6-[[[(naphthalen-1-yl)methyl]sulfonyl]amino]-octahydro-pyrrolo[1,2-a]azepin-5-one-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine lactam,
- 5 i) (3S,6S,9aS)-N<sup>α</sup>-[[6-[(benzylsulfonyl)amino]-octahydro-pyrrolo[1,2-a]azepin-5-one-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine lactam,  
m.p. 88-95°C (dec.),
- 10 l) (3S,6S,9aS)-N<sup>α</sup>-[[6-[[[(naphthalen-1-yl)sulfonyl]amino]-octahydro-pyrrolo[1,2-a]azepin-5-one-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine lactam,  
m.p. 130-135°C (dec.)
- m) (3S,6R\*,9aS)-N<sup>α</sup>-[[6-benzyl-octahydropyrrolo[1,2-a]azepin-5-one-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine lactam,
- 15 <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 0.95-2.50 (m, 13H); 2.83-3.52 (m, 5H); 4.02 (m, 1H); 4.43-4.95 (m, 3H), 5.14 (s, 2H); 7.15-7.50 (m, 10H); 7.80 (d, 1H); 9.50 (m, 2H),
- 20 n) (3S,6R\*,9aS)-N<sup>α</sup>-[[6-benzyl-octahydroindolizin-5-one-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine lactam,  
<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 1.40-2.20 (m, 8H); 2.50-2.83 (m, 4H); 3.21-3.52 (m, 4H); 4.37 (d, 1H); 4.64 (m, 1H); 4.86 (m, 1H); 5.14 (s, 2H); 6.94 (d, 1H); 7.20-7.48 (m, 10H);
- 25 9.50 (m, 2H).

Example 7

(3S,6S,9aS)-N<sup>α</sup>-[[6-(6-acetylamino-octahydropyrrolo[1,2-a]azepin-5-one)-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine aldehyde

- 30 A solution of (3S,6S,9aS)-N<sup>α</sup>-[[6-(6-acetylamino-octahydropyrrolo[1,2-a]azepin-5-one)-3-yl]carbonyl]-N<sup>W</sup>-ben-

25

zyloxycarbonyl-L-arginine aldehyde lactam (0.2 g, 0.38 mmoles) in 5 ml of anhydrous THF, cooled at -20°C and under N<sub>2</sub> atmosphere, is added drop by drop with a suspension of LiAlH<sub>4</sub> (0.010 g, 0.23 mmoles) in 4 ml of anhydrous THF. After 2 h stirring at -20°C, 1N HCl is added to pH 7. The mixture is left to warm at room temperature and the suspension is filtered through Na<sub>2</sub>SO<sub>4</sub>. The solvent is removed under reduced pressure and the resulting residue is purified by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 95:5). 0.18 g of a white amorphous solid are obtained (92% yield).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 0.88 (d, 1H); 1.20-2.25 (m, 16H); 2.05 (s, 3H); 3.10 (m, 1H); 3.50 (m, 1H); 3.82 (m, 1H); 4.40-4.75 (m, 3H); 5.09 (s, 2H); 5.82 (s, 1H); 6.82 (d, 1H); 7.37 (m, 5H); MS (FAB<sup>+</sup>): m/z 529 (MH<sup>+</sup>)

Analogously are prepared:

- a) (3S,6R,8aR)-N<sup>Q</sup>-[[[(6-acetylamino-6-benzyl-octahydro-indolizin-5-one)-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine aldehyde  
 m.p. 95-100°C (dec); <sup>1</sup>H-NMR (CDCl<sub>3</sub>): 0.7 (m, 2H); 1.20-2.10 (m, 14H); 2.10 (s, 3H); 3.05-3.20 (m, 2H); 3.70-4.30 (m, 3H); 5.05 (s, 2H); 5.51 (m, 1H); 6.27 (d, 1H); 7.15-7.49 (m, 10H); MS (FAB<sup>+</sup>): m/z 605 (MH<sup>+</sup>).
- b) (3S,6R\*,7R\*,9aS)-N<sup>Q</sup>-[[[(6-acetylamino-7-methyloctahydro[1,2-a]azepin-5-one)-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine aldehyde,
- c) -N<sup>Q</sup>-[[[(6-acetylamino)-6-benzyl-hexahydropyrrolizin-5-one)-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine aldehyde,
- d) -N<sup>Q</sup>-[[[(6-acetylamino-6-ethylhexahydropyrrolizin-5-one)-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine

- aldehyde,
- e)  $-N^{\alpha}-[[[6\text{-acetylamino-6-methylhexahydropyrrolizin-5-one})-3\text{-yl}] \text{carbonyl}]-N^W\text{-benzyloxycarbonyl-L-arginine}$  aldehyde,
- 5 f)  $(3S,6R^*,7R^*,8aR)-N^{\alpha}-[[[6\text{-amino-7-phenyl-octahydro-indolizin-5-one})-3\text{-yl}] \text{carbonyl}]-N^W\text{-benzyloxycarbonyl-L-arginine}$  aldehyde,
- g)  $(3S,6R^*,8aS)-N^{\alpha}-[[[6\text{-benzyl-octahydroindolizin-5-one})-3\text{-yl}] \text{carbonyl}]-N^W\text{-benzyloxycarbonyl-L-arginine}$  aldehyde,
- 10 m.p. 105-113°C (dec.),
- h)  $(3S,6S,9aS)-N^{\alpha}-[[[6-[(\text{benzylsulfonyl})\text{amino}]\text{-octahydropyrrolo}[1,2\text{-a}]\text{azepin-5-one}]\text{-3-yl}] \text{carbonyl}]-N^W\text{-benzyloxycarbonyl-L-arginine}$  aldehyde,
- 15 i)  $(3S,6S,9aS)-N^{\alpha}-[[[6-[(1\text{-naphthylsulfonyl})\text{amino}]\text{-octahydropyrrolo}[1,2\text{-a}]\text{azepin-5-one}]\text{-3-yl}] \text{carbonyl}]-N^W\text{-benzyloxycarbonyl-L-arginine}$  aldehyde,
- l)  $(3S,6S,9aS)-N^{\alpha}-[[[6-[(2\text{-naphthylsulfonyl})\text{amino}]\text{-octahydropyrrolo}[1,2\text{-a}]\text{azepin-5-one}]\text{-3-yl}] \text{carbonyl}]-N^W\text{-benzyloxycarbonyl-L-arginine}$  aldehyde,
- 20 m)  $(3S,6S,9aS)-N^{\alpha}-[[[6-[(1\text{-naphthylmethyl})\text{sulfonyl}]\text{-amino}]\text{octahydropyrrolo}[1,2\text{-a}]\text{-azepin-5-one}]\text{-3-yl}] \text{carbonyl}]-N^W\text{-benzyloxycarbonyl-L-arginine}$  aldehyde,
- n)  $(3S,6S,9aS)-N^{\alpha}-[[[6-[(3\text{-methylquinolin-8-yl})\text{sulfonyl}]\text{amino}]\text{-octahydropyrrolo}[1,2\text{-a}]\text{azepin-5-one-3-yl}] \text{carbonyl}]-N^W\text{-benzyloxycarbonyl-L-arginine}$  aldehyde,
- 25 m.p. 98-110°C (dec),
- o)  $(3S,6R^*,9aS)-N^{\alpha}-[[[6\text{-benzyl-octahydropyrrolo}[1,2\text{-a}]\text{-azepin-5-one-3-yl}] \text{carbonyl}]-N^W\text{-benzyloxycarbonyl-L-arginine}$  aldehyde.
- 30

Example 8

(3S,6S,9aS)-N<sup>a</sup>-[[[6-acetylamino-octahydropyrrolo[1,2-a]-azepin-5-one]-3-yl]carbonyl]-L-arginine aldehyde hydrochloride

- 5           A solution of (3S,6S,9aS)-N<sup>a</sup>-[[[6-acetylamino-octahydropyrrolo[1,2-a]azepin-5-one]-3-yl]carbonyl]-N<sup>W</sup>-benzyloxycarbonyl-L-arginine aldehyde (0.18 g, 0.34 mmoles) in 10 ml of THF is added with palladium on charcoal (10%, 35 mg) and 0.35 ml of 1N HCl. The mixture is placed under hydrogen atmosphere and left to react under stirring until the starting product disappears, then it is filtered through Celite and the solvent is removed under reduced pressure. Upon grinding with Et<sub>2</sub>O, 0.13 g of a white amorphous solid are obtained (88% yield).
- 10
- 15           m.p. 125-135°C (dec); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.95 (m, 1H); 1.30-2.20 (m, 13H); 2.07 (s, 3H); 3.07-3.42 (m, 3H); 3.82 (m, 2H); 4.50 (m, 2H); 7.03 (m, 1H); 7.51-7.85 (m, 4H); 9.45 (s, 1H); MS (FAB<sup>+</sup>): m/z 395 (MH<sup>+</sup>).

Analogously are prepared:

- 20           a) (3S,6R,8aR)-N<sup>a</sup>-[[[6-acetylamino-6-benzyl-octahydroindolizin-5-one)-3-yl]carbonyl]-L-arginine aldehyde hydrochloride
- m.p. 148-152°C (dec); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.71-1.05 (m, 2H); 1.25-2.30 (m, 12H); 2.07 (s, 3H); 3.20-3.48 (m, 2H); 3.60-3.75 (m, 1H); 4.05-4.46 (m, 3H); 6.51 (s, 1H); 7.05-7.20 (m, 5H); 7.58 (m, 4H); 9.52 (s, 1H)
- 25           MS (FAB<sup>+</sup>): m/z 471 (MH<sup>+</sup>).
- b) (3S,6R<sup>\*</sup>,7R<sup>\*</sup>,9aS)-N<sup>a</sup>-[[[6-acetylamino-7-methyloctahydropyrrolo[1,2-a]azepin-5-one)-3-yl]carbonyl]-L-arginine aldehyde hydrochloride,
- 30           c) (3S,6R<sup>\*</sup>,7aR)-N<sup>a</sup>-[[[6-acetylamino-6-benzyl-hexahy-

28

dropyrrolizin-5-one)3-yl]carbonyl]-L-arginine  
aldehyde hydrochloride,

- d) (3S,6R\*,7aR)-N<sup>Q</sup>-[[[(6-acetylamino-6-ethylhexahydro-  
pyrrolizin-5-one)3-yl]carbonyl]-L-arginine aldehyde  
5 hydrochloride,
- e) (3S,6R\*,7aR)-N<sup>Q</sup>-[[[(6-acetylamino-6-methylhexahydro-  
pyrrolizin-5-one)-3-yl]carbonyl]-L-arginine aldehy-  
de hydrochloride,
- f) (3S,6R\*,7R\*,8aR)-N<sup>Q</sup>-[[[(6-amino-7-phenyl-octahydro-  
10 indolizin-5-one)-3-yl]carbonyl]-L-arginine aldehyde  
hydrochloride,
- g) (3S,6R\*,8aS)-N<sup>Q</sup>-[[[(6-benzyl-octahydroindolizin-5-  
one)3-yl]carbonyl]-L-arginine aldehyde hydrochlo-  
ride,
- 15 m.p. 115-122°C (dec.); MS (FAB<sup>+</sup>): m/z 414 (MH<sup>+</sup>)
- h) (3S,6S,9aS)-N<sup>Q</sup>-[[[6-[(benzylsulfonyl)amino]-octahy-  
dropyrrolo[1,2a]azepin-5-one]3-yl]carbonyl]-L-argi-  
nine aldehyde hydrochloride,  
m.p. 95-110°C (dec.); MS (FAB<sup>+</sup>): m/z 507 (MH<sup>+</sup>)
- 20 i) (3S,6S,9aS)-N<sup>Q</sup>-[[[6-[(1-naphthylsulfonyl)amino]-  
octahdropyrrolo[1,2-a]azepin-5-one]-3-yl]carbo-  
nyl]-L-arginine aldehyde hydrochloride,  
m.p. 103-107°C (dec.); MS (FAB<sup>+</sup>): m/z 543 (MH<sup>+</sup>)
- 25 l) (3S,6S,9aS)-N<sup>Q</sup>-[[[6-[(2-naphthylsulfonyl)amino]-  
octahdropyrrolo[1,2-a]azepin-5-one]-3-yl]carbo-  
nyl]-L-arginine aldehyde hydrochloride,
- m) (3S,6S,9aS)-N<sup>Q</sup>-[[[6-[[[(1-naphthylmethyl)sulfonyl]-  
amino]-octahdropyrrole[1,2-a]-azepin-5-one]-3-yl]-  
carbonyl]-L-arginine aldehyde hydrochloride,
- 30 n) (3S,6S,9aS)-N<sup>Q</sup>-[[[6-[[[(3-methylquinolin-8-yl)sulfo-  
nyl]amino]-octahdropyrrolo[1,2-a]azepin-5-one]-3-

29

yl]carbonyl]-arginine aldehyde hydrochloride,

MS (FAB<sup>+</sup>): m/z 558 (MH<sup>+</sup>),

o) (3S,6R\*,9aS)-N<sup>Q</sup>-[[6-benzyl-octahydropyrrolo[1,2-a]-  
azepin-5-one-3-yl]carbonyl]-L-arginine aldehyde hy-  
drochloride,

m.p. 92-105°C (dec.); MS (FAB<sup>+</sup>): m/z 428 (MH<sup>+</sup>),

p) (3S,6S,9aS)-N<sup>Q</sup>-[[6-[[[(3-methyl-1,2,3,4-tetrahydro-  
quinolin-8-yl)sulfonyl]amino]-octahydropyrrolo[1,2-  
a]azepin-5-one-3-yl]carbonyl]-L-arginine aldehyde  
hydrochloride,

m.p. 170-175°C (dec.); MS (FAB<sup>+</sup>): m/z 562 (MH<sup>+</sup>).Example 9

(3S,6S,9aS)-6-amino-3-(t-butoxycarbonyl)-octahydropyrro-  
lo[1,2-a]azepin-5-one

A solution of (3S,6S,9aS)-6-[(benzyloxycarbonyl)-  
amino]-3-(t-butoxycarbonyl)-octahydropyrrolo[1,2-a]aze-  
pin-5-one (5.03 g, 12.4 mmol) in 200 ml of MeOH, si  
added with palladium on charcoal (10%, 0.35 g). The  
mixture is placed under hydrogen atmosphere and reacted  
with stirring until the starting compound disappears.  
The suspension is filtered through celite, solvent is  
removed under reduced pressure and the residue is dried  
in a drier with P<sub>2</sub>O<sub>5</sub> at room temperature. 2.77 g of a  
transparent, sticky residue are obtained (83% yield).  
<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 1.47 (s, 9H); 1.50-2.31 (m, 10H); 3.42  
(d, 1H); 3.75 (m, 1H); 4.52 (m, 1H).

Example 10

(3S,6S,9aS)-6-[(benzylsulfonyl)amino]-3-(t-butoxycarbo-  
nyl)-octahydropyrrolo[1,2-a]azepin-5-one

A solution of (3S,6S,9aS)-6-amino-3-(t-butoxycar-  
bonyl)-octahydropyrrolo[1,2-a]azepin-5-one (1.2 g, 4.47

30

mmoles) in 30 ml of  $\text{CH}_2\text{Cl}_2$  is added with triethylamine (1 ml, 5.81 mmoles), then with benzylsulfonyl chloride (1.02 g, 5.36 mmoles).

5 The mixture is stirred at room temperature for 4 h, washed with a 5% citric acid solution, with water, finally with a NaCl saturated solution, then it is dried over  $\text{Na}_2\text{SO}_4$  and solvent is removed under reduced pressure. The resulting sticky residue is purified by flash chromatography (eluent: hexane/EtOAc 1:1).

10 After purification, 1.70 g of the pure product are obtained in the form of a waxy solid (89% yield).

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$ : 1.48 (s, 9H); 1.48-2.20 (m, 10H); 3.17 (m, 1H); 3.32 (m, 1H); 4.10-4.48 (m, 3H); 5.87 (d, 1H); 7.25-7.48 (m, 5H).

15 Analogously are prepared:

(3S,6S,9aS)-6-[[naphthalen-1-yl]sulfonyl]amino]-3-(t-butoxycarbonyl)-octahydropyrrolo[1,2-a]azepin-5-one

20  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$ : 1.47 (s, 9H); 1.50-2.23 (m, 10H); 3.56 (s, 1H); 3.88 (s, 1H); 4.34 (t, 1H); 6.50 (d, 1H); 7.48-7.72 (m, 3H); 7.95 (d, 1H); 8.04 (d, 1H); 8.23 (d, 1H); 8.68 (d, 1H).


(3S,6S,9aS)-3-(t-butoxycarbonyl)-6-[[3-methylquinolin-8-yl]sulfonyl]amino]-octahydropyrrolo[1,2-a]azepin-5-one

25  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$ : 1.48 (s, 9H); 1.50-2.37 (m, 10H); 2.63 (s, 3H); 3.60 (m, 1H); 4.04 (m, 1H); 4.29 (m, 1H); 7.52 (m, 2H); 8.01 (m, 2H); 8.28 (d, 1H); 8.93 (d, 1H).



CLAIMS

1. Compounds of general formula I:




wherein:

- m is 0, 1, 2 or 3;
- R<sub>1</sub> is a group of formula -CHO, -CH<sub>2</sub>OH, COOH, -B(OH)<sub>2</sub>;
- R<sub>2</sub>, R<sub>3</sub> are independently hydrogen, COOR<sub>7</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, benzyl, -NO<sub>2</sub>;
- R<sub>4</sub>, R<sub>5</sub> are independently hydrogen, NR<sub>8</sub>R<sub>9</sub>, straight or branched C<sub>1</sub>-C<sub>7</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or an arylalkyl or heteroarylalkyl group, optionally substituted at the ring with one or more substituents such as halogen (Cl, Br, I), methoxyl, trifluoromethyl, straight or branched C<sub>1</sub>-C<sub>7</sub> alkyl;
- R<sub>6</sub> is hydrogen, straight or branched C<sub>1</sub>-C<sub>7</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or an aryl, heteroaryl, arylalkyl or heteroarylalkyl group, optionally substituted at the ring with one or more substituents such as halogen (Cl, Br, I), methoxy, trifluoromethyl, straight or branched C<sub>1</sub>-C<sub>7</sub> alkyl;
- R<sub>7</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl, benzyl;
- R<sub>8</sub>, R<sub>9</sub> are independently hydrogen, straight or

32

branched C<sub>1</sub>-C<sub>7</sub> alkyl or a group of general formula  
-W-Q wherein:



      -    Q can be a phenyl, benzyl, naphthyl, quinolyl,  
naphthylmethyl, tetrahydroquinolyl, tetrahydroiso-  
quinolyl group, optionally substituted with one or  
more groups such as halogen (Cl, Br, I), straight  
10        or branched C<sub>1</sub>-C<sub>7</sub> alkyl, methoxy, trifluoromethyl,  
the stereoisomeric forms thereof and the salts  
thereof with pharmaceutically acceptable acids.

2.    Compounds according to claim 1, wherein m is 2, R<sub>1</sub>  
is -CHO, R<sub>6</sub> is hydrogen and R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> have the  
15        meanings reported above.

3.    As compounds according to claim 2:

(3S,6S,9aS)-N<sup>d</sup>-[[6-acetylamino-octahydropyrrolo[1,2-a]-  
azepin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

20        (3S,6S,9aS)-N<sup>d</sup>-[[6-methylamino-octahydropyrrolo[1,2-a]-  
azepin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

(3S,6S,9aS)-N<sup>d</sup>-[[6-[[[naphthalen-1-yl)sulfonyl]amino]-  
octahydropyrrolo-[1,2-a]azepin-5-one-3-yl]carbonyl]-L-  
arginine aldehyde,

25        (3S,6R\*,9aS)-N<sup>d</sup>-[[6-benzyl-octahydropyrrolo-[1,2-a]aze-  
pin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

(3S,6S,9aS)-N<sup>d</sup>-[[6-[(benzylsulfonyl)amino]-octahydropyr-  
rolo-[1,2-a]azepin-5-one-3-yl]carbonyl]-L-arginine alde-  
hyde,

30        (3S,6S,9aS)-N<sup>d</sup>-[[6-[[[naphthalen-1-yl)methyl]sulfonyl]-  
amino]-octahydropyrrolo[1,2-a]azepin-5-one-3-yl]carbo-  
nyl]L-arginine aldehyde,

(3S,6S,9aS)-N<sup>a</sup>-[[6-[[[(naphthalen-2-yl)methyl]sulfonyl]-amino]-octahydropyrrolo[1,2-a]azepin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

5 (3S,6S,9aS)-N<sup>a</sup>-[[6-[[[(3-methylquinolin-8-yl)sulfonyl]-amino]-octahydropyrrolo[1,2-a]azepin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

(3S,6S,9aS)-N<sup>a</sup>-[[6-[[[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonyl]amino]octahydropyrrolo[1,2-a]azepin-5-one-3-yl]carbonyl]-L-arginine aldehyde.

10 4. Compounds according to claim 1, wherein m is 1, R<sub>1</sub> is -CHO and R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> have the meanings reported above.

5. As compounds according to claim 4:

15 (3S,6S,8aS)-N<sup>a</sup>-[[6-benzyl-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

(3S,6R,8aS)-N<sup>a</sup>-[[6-benzyl-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

(3S,6S,8aS)-N<sup>a</sup>-[[6-[(thiophen-2-yl)methyl]-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

20 (3S,6R,8aS)-N<sup>a</sup>-[[6-[(thiophen-2-yl)methyl]-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

(3S,6S,8aS)-N<sup>a</sup>-[[6-[(naphthalen-2-yl)methyl]octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

25 (3S,6R,8aS)-N<sup>a</sup>-[[6-[(naphthalen-2-yl)methyl]octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,


(3S,6S,8aS)-N<sup>a</sup>-[[6-[(naphthalen-1-yl)methyl]-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

(3S,6R,8aS)-N<sup>a</sup>-[[6-[(naphthalen-1-yl)methyl]-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,


30 (3S,6R,8aR)-N<sup>a</sup>-[[6-acetylamino-6-benzyl-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,

34

- (3S,6S,8aR)-N<sup>d</sup>-[[6-acetylamino-6-benzyl-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,  
 (3S,6S,8aR)-N<sup>d</sup>-[[6-benzyl-6-methylamino-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,  
 5 (3S,6R,8aR)-N<sup>d</sup>-[[6-benzyl-6-methylamino-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,  
 (3S,6S,8aR)-N<sup>d</sup>-[[6-benzyl-6-[(t-butoxycarbonyl)amino]-octahydroindolizin-5-one]-3-yl]-L-arginine aldehyde,  
 (3S,6R,8aR)-N<sup>d</sup>-[[6-benzyl-6-[(t-butoxycarbonyl)amino]-octahydroindolizin-5-one]-3-yl]-L-arginine aldehyde,  
 10 (3S,6R\*,7R\*,8aR)-N<sup>d</sup>-[[6-amino-7-phenyl-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,  
 (3S,6R\*,7R\*,8aR)-N<sup>d</sup>-[[6-(methylamino)-7-phenyl-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,  
 15 (3S,6R\*,7R\*,8aR)-N<sup>d</sup>-[[6-(acetylamino)-7-phenyl-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde,  
 (3S,6R\*,7R\*,8aR)-N<sup>d</sup>-[[6-(acetylamino)-7-methyl-octahydroindolizin-5-one-3-yl]carbonyl]-L-arginine aldehyde.
6. A process for the preparation of the compounds of  
 20 general formula I, which comprises the condensation reaction of intermediates of general formula III wherein m and R<sub>10</sub> have the meanings reported above and X is -OH, with compounds of general formula II, wherein R<sub>4</sub> (R<sub>5</sub>) and R<sub>6</sub> have the meanings reported  
 25 above



(II)




(III)


30

35


to give compounds of general formula IV', which are transformed into compounds of general formula IV, wherein X is Br, I, Se-C<sub>6</sub>H<sub>5</sub>



which are cyclized to compounds of general formula V




20 which are subjected to hydrolysis of the carboxylic group (R<sub>10</sub> = H) and coupled with intermediates of general formula VI



30 to give compounds of general formula VII

36


5



(VII)

which are reduced to give compounds of general formula VIII

10



(VIII)

15

which are subjected to removal of the protecting groups  $R_2$  ( $R_3$ ) and treatment with organic or inorganic acids, to yield compounds of general formula I.

20

7. The use of the compounds of claims 1-5 as therapeutic agents for use as antithrombotic, anticoagulant or antiplatelet agents.

8. Pharmaceutical compositions containing as active principle an effective amount of one or more compounds

25

of claims 1-5, in admixture with suitable excipients.

# INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/EP 96/03167

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6 C07K5/06 C07D487/04 C07D471/04 A61K31/395 //(C07D487/04,209:00,209:00),(C07D471/04,221:00,209:00), (C07D487/04,223:00,209:00),(C07D487/04,225:00,209:00) According to International Patent Classification (IPC) or to both national classification and IPC														
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07K C07D A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used)														
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category *</th> <th style="width: 70%;">Citation of document, with indication, where appropriate, of the relevant passages</th> <th style="width: 20%;">Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td>EP,A,0 526 877 (SQUIBB BRISTOL MYERS CO) 10 February 1993 cited in the application see the whole document ---</td> <td style="text-align: center; vertical-align: top;">1-8</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td>DE,A,41 21 947 (BASF AG) 7 January 1993 see the whole document ---</td> <td style="text-align: center; vertical-align: top;">1-8</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td>TETRAHEDRON, vol. 49, no. 17, 1993, pages 3577-3592, XP000576111 U.NAGAI E.A.: "Bicyclic turned dipeptide (BTD) as a beta-turn mimetic;..." see the whole document --- -/--</td> <td style="text-align: center; vertical-align: top;">1-8</td> </tr> </tbody> </table>			Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	Y	EP,A,0 526 877 (SQUIBB BRISTOL MYERS CO) 10 February 1993 cited in the application see the whole document ---	1-8	Y	DE,A,41 21 947 (BASF AG) 7 January 1993 see the whole document ---	1-8	Y	TETRAHEDRON, vol. 49, no. 17, 1993, pages 3577-3592, XP000576111 U.NAGAI E.A.: "Bicyclic turned dipeptide (BTD) as a beta-turn mimetic;..." see the whole document --- -/--	1-8
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
Y	EP,A,0 526 877 (SQUIBB BRISTOL MYERS CO) 10 February 1993 cited in the application see the whole document ---	1-8												
Y	DE,A,41 21 947 (BASF AG) 7 January 1993 see the whole document ---	1-8												
Y	TETRAHEDRON, vol. 49, no. 17, 1993, pages 3577-3592, XP000576111 U.NAGAI E.A.: "Bicyclic turned dipeptide (BTD) as a beta-turn mimetic;..." see the whole document --- -/--	1-8												
<div style="display: flex; justify-content: space-between;"> <span><input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.</span> <span><input checked="" type="checkbox"/> Patent family members are listed in annex.</span> </div>														
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>														
Date of the actual completion of the international search  <div style="text-align: center; font-size: 1.2em;">16 December 1996</div>		Date of mailing of the international search report  <div style="text-align: center; font-size: 1.2em;">18.12.96</div>												
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016		Authorized officer  <div style="text-align: center; font-size: 1.2em;">Groenendijk, M</div>												

# INTERNATIONAL SEARCH REPORT

Int. l. Application No  
PCT/EP 96/03167

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>WO,A,96 19483 (BIOCHEM PHARMA INC ;DIMAIO JOHN (CA); SIDDIQI M ARSHAD (CA); GILL) 27 June 1996 see claims 1,2,6-9,30,31,35-38,50-5; table 7</p> <p>-----</p>	1,4,6-8



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 96/03167

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 7  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 7 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/03167

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0526877	10-02-93	CA-A- 2075154	07-02-93
		JP-A- 7242616	19-09-95
		US-A- 5380713	10-01-95
-----			
DE-A-4121947	07-01-93	CA-A- 2112580	21-01-93
		WO-A- 9301208	21-01-93
		EP-A- 0668869	30-08-95
		JP-T- 6509076	13-10-94
		US-A- 5489583	06-02-96
-----			
WO-A-9619483	27-06-96	AU-A- 4062795	27-06-96
		AU-A- 4062895	04-07-96
		AU-A- 4250596	10-07-96
		AU-A- 4250896	10-07-96
		WO-A- 9619491	27-06-96
		ZA-A- 9510960	09-07-96
		ZA-A- 9510961	09-07-96
-----			